Dai Advances in Nanotheranostics I

Design and Fabrication of Theranosic Nanoparticles
1. Auflage 2015
ISBN: 978-3-662-48544-6
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 338 Seiten

Reihe: Engineering (R0)

This book highlights the recent advances in nanotheranostics from basic research to potential applications, and discusses the modular design and engineering of multiplex nanoparticles including gold nanostructures, luminescent nanoparticles, dendrimers and liposomes. Each chapter demonstrates multifunctional nanoparticles with topics covering targeting, imaging, delivery, diagnostics, and therapy as new modalities for cancer theranostics. This comprehensive book presents expert views on the latest developments in theranostic nanomedicine. It focuses on potential theranostic applications of multifunctional nanoparticles ranging from identifying noninvasively cancer cells by molecular detection, and visualizing in vivo drug delivery by means of contrast enhanced imaging, to destroying cancer cell s with minimal side effects via selective accumulation at tumor sites, and real-time monitoring therapeutic effectiveness. It also presents an interdisciplinary survey of nanotheranostics and as such is a valuable resource for researchers and students in related fields. Zhifei Dai is a Professor at the Department of Biomedical Engineering, College of Engineering, Peking University, China.

Prof. Zhifei Dai obtained his Ph.D. in Physical Chemistry at the Institute of Photographic Chemistry, Chinese Academy of Sciences in 1998. From 1999 to 2005, he worked at the School of Sciences, Kwansei Gakuin University in Japan, Max-Planck Institute of Colloids and Interfaces in Germany, and the School of Medicine, Emory University in USA, respectively. In March 2005, he became a Professor at the School of Life Science and Technology, Harbin Institute of Technology, China. In May 2012, he moved to the Department of Biomedical Engineering, College of Engineering, Peking University, China. His research focuses on the multifunctional nanoparticles for drug delivery and contrast enhanced imaging. He is a member of editorial board for several international and national journals such as Bioconjugate Chemistry, Theranostics, Journal of Interdisciplinary Nanomedicine, IET Nanobiotechnology, BioMed International Research, Chinese Journal of Nuclear Medicine and Molecular Imaging and so on. He is now a standing committee member of China Association of Medical Ultrasound Equipment and Chinese Association of Ultrasound in Medicine and Engineering, an executive member of the council of Chinese Society for Functional Materials, and a committee member of the Acoustic Society of China. He received many honors and awards including National Natural Science Fund for Outstanding Young Researcher, New Century Talents of Chinese Ministry of Education, Longjiang Scholar Distinguished Professor, and the First Prize of the Natural Science Award of Heilongjiang Province.

Autoren/Hrsg.

Dai, Zhifei

Inhaltsverzeichnis

1;Preface;6
2;Contents;8
3;Part I: Gold Nanostructures Based Theranostics;10
3.1;Chapter 1: Near-Infrared Light-Mediated Gold Nanoplatforms for Cancer Theranostics;11
3.1.1;1.1 Introduction;12
3.1.2;1.2 Near-Infrared Light-Mediated Cancer Imaging by Au Nanostructures;12
3.1.2.1;1.2.1 Dark-Field Microscopy;14
3.1.2.2;1.2.2 Two-Photon Luminescence (TPL);16
3.1.2.3;1.2.3 Photoacoustic Tomography (PAT);18
3.1.2.4;1.2.4 X-ray Computed Tomography (CT);19
3.1.2.5;1.2.5 Optical Coherence Tomography (OCT);20
3.1.2.6;1.2.6 Surface-Enhanced Raman Scattering (SERS);21
3.1.3;1.3 Cancer Photothermal Therapy by Au Nanostructures;22
3.1.4;1.4 Functionalization of Au Nanostructures;24
3.1.4.1;1.4.1 Noncovalent Functionalization;26
3.1.4.2;1.4.2 Covalent Functionalization;27
3.1.5;1.5 Au Nanoshells (AuNSs);28
3.1.6;1.6 Au Nanorods (AuNRs);31
3.1.7;1.7 Hollow Au Nanospheres (HAuNSs);33
3.1.8;1.8 Au Nanocages (AuNCs);36
3.1.9;1.9 Au Nanostars;38
3.1.10;1.10 Other Au Nanostructures;40
3.1.11;1.11 Strategy for Combatting Cancer Drug Resistance and Inhibiting Cancer Stem Cells and Cancer Metastasis;42
3.1.12;1.12 Conclusions and Perspectives;45
3.1.13;References;51
3.2;Chapter 2: Gold Nanostructures for Cancer Imaging and Therapy;61
3.2.1;2.1 Introduction;61
3.2.2;2.2 Plasmonic Properties and Surface Functionalization of Gold Nanostructures;62
3.2.2.1;2.2.1 Radiative Properties;62
3.2.2.2;2.2.2 Nonradiative Photothermal Effects;66
3.2.2.3;2.2.3 Surface Functionalization;67
3.2.3;2.3 Gold Nanostructures for Photothermal Therapy;69
3.2.3.1;2.3.1 Gold Nanoshells;71
3.2.3.2;2.3.2 Gold Nanorods;74
3.2.3.3;2.3.3 Gold Nanocages;76
3.2.3.4;2.3.4 Other Gold Nanostructures;77
3.2.4;2.4 Combination of Photothermal Therapy with Other Therapeutic Approaches;79
3.2.4.1;2.4.1 Combination of Photothermal Therapy with Photodynamic Therapy;79
3.2.4.2;2.4.2 Combination of Photothermal Therapy with Chemotherapy;81
3.2.5;2.5 Gold Nanostructures for Diagnostics;84
3.2.5.1;2.5.1 Dark-Field Imaging (DFI);84
3.2.5.2;2.5.2 Optical Coherence Tomography;85
3.2.5.3;2.5.3 Two-Photon Luminescence;87
3.2.5.4;2.5.4 Photoacoustic Imaging;88
3.2.5.5;2.5.5 Computed Tomography;90
3.2.5.6;2.5.6 Surface-Enhanced Raman Scattering (SERS) Based Imaging;91
3.2.6;2.6 Gold Nanostructures for Imaging-Guided Therapy;94
3.2.7;2.7 Concluding Remarks;97
3.2.8;References;97
3.3;Chapter 3: Gold Nanorods for Biomedical Imaging and Therapy in Cancer;110
3.3.1;3.1 Introduction;110
3.3.2;3.2 Gold Nanorod Synthesis;112
3.3.3;3.3 Surface Modification and Functionalization;119
3.3.4;3.4 Properties;123
3.3.4.1;3.4.1 Localized Surface Plasmon Resonance Effect;124
3.3.4.2;3.4.2 Surface-Enhanced Raman Scattering;125
3.3.4.3;3.4.3 Single-/Two-Photon Fluorescence;125
3.3.4.4;3.4.4 Near-Field Plasmon Coupling;125
3.3.4.5;3.4.5 Photosensitive Effect;126
3.3.5;3.5 Biomedical Applications;126
3.3.5.1;3.5.1 AuNRs as Biomedical Imaging Agents;127
3.3.5.1.1;3.5.1.1 Light Scattering Imaging;127
3.3.5.1.2;3.5.1.2 Two-Photon Fluorescence Imaging;128
3.3.5.1.3;3.5.1.3 Photoacoustic Imaging;129
3.3.5.2;3.5.2 AuNRs for Cancer Therapy;130
3.3.5.2.1;3.5.2.1 Drug/Gene Therapy;130
3.3.5.2.2;3.5.2.2 Photothermal Therapy;131
3.3.5.2.3;3.5.2.3 Photodynamic Therapy;132
3.3.5.2.4;3.5.2.4 Combined Applications;133
3.3.5.3;3.5.3 AuNRs for New Applications;134
3.3.5.3.1;3.5.3.1 New Unique Way to Challenge Drug Resistance;135
3.3.5.3.2;3.5.3.2 Localized Electric Field of Plasmonic AuNR-Enhanced Photodynamic Therapy;135
3.3.5.3.3;3.5.3.3 Highly Efficient and Safe Photodynamic Therapy;137
3.3.6;3.6 Perspectives;137
3.3.7;References;138
4;Part II: Theranostic Luminescent Nanoparticles;144
4.1;Chapter 4: Lanthanide-Doped Upconversion Nanoparticles for Imaging-Guided Drug Delivery and Therapy;145
4.1.1;4.1 Introduction;145
4.1.2;4.2 Engineering of UCNPs for Biomedical Applications;146
4.1.2.1;4.2.1 Basic Mechanism of UCNPs;146
4.1.2.2;4.2.2 Synthesis of UCNPs;147
4.1.2.3;4.2.3 UCNPs with Core@shell Structures;148
4.1.2.4;4.2.4 Surface Modification for Upconversion Enhancing and Bio-conjugation;151
4.1.3;4.3 Biosafety of UCNPs;154
4.1.3.1;4.3.1 Internalization of UCNPs into Cells;154
4.1.3.2;4.3.2 Biodistributions of Injected UCNPs in Mice Models;154
4.1.3.3;4.3.3 Excretion of UCNPs;155
4.1.3.4;4.3.4 Cellular and In Vivo Toxicity of UCNPs;156
4.1.4;4.4 UCNPs as Imaging Contrast Reagents;157
4.1.5;4.5 UCNPs as Drug Delivery Nanoplatform;159
4.1.5.1;4.5.1 UCNPs as Traditional Drug Delivery Tools;159
4.1.5.2;4.5.2 Light-Controllable Drug Release Based on UCNPs;161
4.1.5.3;4.5.3 UCNPs for Gene Delivery;162
4.1.6;4.6 UCNPs as Phototherapeutic Reagents;163
4.1.6.1;4.6.1 Photodynamic Therapy;163
4.1.6.2;4.6.2 Photothermal Therapy;166
4.1.6.3;4.6.3 Combined PDT/PTT;166
4.1.7;4.7 Conclusion and Prospects;167
4.1.8;References;168
4.2;Chapter 5: Engineering Upconversion Nanoparticles for Multimodal Biomedical Imaging-Guided Therapeutic Applications;171
4.2.1;5.1 Introduction;171
4.2.2;5.2 Hydrophilic Surface Modification of UCNPs;173
4.2.2.1;5.2.1 Polymer Coating Modification;173
4.2.2.2;5.2.2 Ligand-Free Synthesis Modification;174
4.2.2.3;5.2.3 Silica Coating Modification;174
4.2.3;5.3 Engineering UCNPs for Multimodal Biomedical Imaging;175
4.2.3.1;5.3.1 UCNPs for Single-Modality UCL Imaging;175
4.2.3.1.1;5.3.1.1 UCNPs for Multicolor UCL Imaging;175
4.2.3.1.2;5.3.1.2 UCNPs for Tracking UCL Imaging;177
4.2.3.1.3;5.3.1.3 UCNPs for Tumor-Targeted UCL Imaging;178
4.2.3.1.4;5.3.1.4 UCNPs for Vascular UCL Imaging;179
4.2.3.1.5;5.3.1.5 UCNPs for Lymphatic UCL Imaging;179
4.2.3.1.6;5.3.1.6 UCNPs for Hypoxic UCL Imaging;181
4.2.3.2;5.3.2 UCNPs for Multimodal Imaging;181
4.2.3.2.1;5.3.2.1 UCNPs for MR/UCL Bimodal Imaging;181
4.2.3.2.2;5.3.2.2 UCNPs for UCL/MRI/CT (PET/SPECT) Trimodal Imaging;184
4.2.3.2.3;5.3.2.3 UCNPs for UCL/MRI/CT/SPECT Four-Modal Imaging;187
4.2.4;5.4 Engineering UCNPs for Imaging-Guided Synergetic Therapy;187
4.2.4.1;5.4.1 UCNPs for PDT;188
4.2.4.2;5.4.2 UCNPs for Radiotherapy;191
4.2.4.3;5.4.3 UCNPs for Synergetic Therapy;193
4.2.5;5.5 Summary and Outlook;194
4.2.6;References;195
4.3;Chapter 6: Multifunctional Quantum Dot-Based Nanoscale Modalities for Theranostic Applications;202
4.3.1;6.1 Quantum Dot;203
4.3.1.1;6.1.1 Optical Imaging;203
4.3.1.2;6.1.2 Quantum Dot Fluorescence Characteristics;203
4.3.1.3;6.1.3 Quantum Dot Synthesis and Composition;204
4.3.1.4;6.1.4 Quantum Dot Solubilisation and Functionalisation;205
4.3.1.5;6.1.5 Quantum Dot in Biomedical Application;206
4.3.1.6;6.1.6 Quantum Dot Biodistribution and Pharmacokinetics In Vivo;207
4.3.1.7;6.1.7 Toxicity Profiles of Non-functionalised Quantum Dot;208
4.3.2;6.2 Quantum Dot for Theranostic Applications;209
4.3.2.1;6.2.1 Quantum Dot-Based Gene Therapy Modalities;209
4.3.2.2;6.2.2 Quantum Dot-Based Chemotherapy Modalities;212
4.3.2.3;6.2.3 Quantum Dot-Based Photodynamic Therapy Modalities;213
4.3.3;6.3 Conclusion;214
4.3.4;References;214
4.4;Chapter 7: Organic Dye-Loaded Nanoparticles for Imaging-Guided Cancer Therapy;222
4.4.1;7.1 Introduction of Organic Dye;222
4.4.1.1;7.1.1 ICG;223
4.4.1.2;7.1.2 IR 700;224
4.4.1.3;7.1.3 IR 780;225
4.4.1.4;7.1.4 IR825;225
4.4.1.5;7.1.5 Ce6;226
4.4.1.6;7.1.6 FITC;226
4.4.2;7.2 Organic Dye for Imaging-Guided Surgical Therapy;227
4.4.3;7.3 Organic Dye-Conjugated Antibody for Imaging-Guided Photoimmunotherapy;229
4.4.4;7.4 Organic Dye-Loaded Inorganic Nanoparticles for Imaging-Guided Phototherapy;230
4.4.4.1;7.4.1 Calcium Phosphosilicate Nanoparticles;230
4.4.4.2;7.4.2 Poly(allylamine hydrochloride)-Assembled Mesocapsules;232
4.4.4.3;7.4.3 SiO2 Nanoparticles;233
4.4.5;7.5 Organic Dye-Loaded Organic Nanoparticles for Imaging-Guided Phototherapy;234
4.4.5.1;7.5.1 Dye-Loaded Polymeric Nanomicelles for Imaging-­Guided Tumor Phototherapy;234
4.4.5.2;7.5.2 Poly(ethylene glycol)–Distearoylphosphatidylethanolamine Block Copolymers (DSPE–PEG) Nanomicelles;235
4.4.5.3;7.5.3 PEG-b-poly(aspartate) (PEG–PAsp) Block Copolymer Nanomicelles;237
4.4.5.4;7.5.4 Surfactant Micelles;239
4.4.5.5;7.5.5 Polypeptide Micelles;240
4.4.5.6;7.5.6 Pluronic F-127 Micelles;240
4.4.5.7;7.5.7 Dye-Loaded PLGA for Imaging-Guided Tumor Phototherapy;241
4.4.5.8;7.5.8 Dye-Loaded Protein Nanoparticles for Imaging-Guided Tumor Phototherapy;242
4.4.5.9;7.5.9 Dye-Loaded Ferritin Nanocages;242
4.4.5.10;7.5.10 Dye-Loaded Albumin Nanoparticles;243
4.4.6;7.6 Prospects and Outlook;246
4.4.7;References;246
5;Part III: Dendrimers and Liposomes for Theranostics;251
5.1;Chapter 8: Dendrimer-Based Nanodevices as Contrast Agents for MR Imaging Applications;252
5.1.1;8.1 Introduction;253
5.1.2;8.2 Dendrimer-Based Complexes for T1-Weighted MR Imaging;254
5.1.2.1;8.2.1 Dendrimer-Gd Complexes;254
5.1.2.1.1;8.2.1.1 Dendrimer-Gd Complexes;254
5.1.2.1.2;8.2.1.2 Multifunctional Dendrimer-Gd Complexes for Targeted Tumor MR Imaging;256
5.1.2.2;8.2.2 Dendrimer-Based Mn Complexes;257
5.1.3;8.3 Dendrimer-Based Iron Oxide Nanoparticles for T2-­Weighted MR Imaging;260
5.1.3.1;8.3.1 Dendrimer-Based Iron Oxide Nanoparticles;260
5.1.3.1.1;8.3.1.1 Dendrimer-Stabilized IO NPs;260
5.1.3.1.2;8.3.1.2 Dendrimer-Assembled IO NPs;261
5.1.3.2;8.3.2 Dendrimer-Modified Lanthanide T2 MR Imaging Contrast Agents;261
5.1.4;8.4 Dendrimer-Based Systems for Dual Modality Imaging;263
5.1.4.1;8.4.1 Dendrimer-Based Dual-Mode MR/CT Imaging Contrast Agents;263
5.1.4.2;8.4.2 Dendrimer-Based MR/Fluorescence Dual-Mode Imaging Applications;264
5.1.5;8.5 Conclusion and Outlooks;267
5.1.6;References;267
5.2;Chapter 9: Functional Dendritic Polymer-Based Nanoscale Vehicles for Imaging-Guided Cancer Therapy;274
5.2.1;9.1 Introduction;275
5.2.2;9.2 Dendritic Architectures;277
5.2.3;9.3 Dendritic Polymer-Based Imaging Probes for Cancer Diagnosis;277
5.2.4;9.4 Dendritic Polymer-Based Drug Delivery Systems for Cancer Therapy;282
5.2.5;9.5 Dendritic Polymer-Based Nanosystems for Cancer Therapy Guided by Imaging;285
5.2.5.1;9.5.1 Near-Infrared-Based Dendritic Nanosystems;287
5.2.5.2;9.5.2 Dendritic Theranostic Nanosystems for Photodynamic Therapy;291
5.2.5.3;9.5.3 Magnetic Resonance Imaging-Based Dendritic Nanosystems;292
5.2.6;9.6 Conclusion;294
5.2.7;References;295
5.3;Chapter 10: Multifunctional Liposomes for Imaging-­Guided Therapy;303
5.3.1;10.1 Introduction;304
5.3.2;10.2 Liposome Properties in Theranostic Design;305
5.3.2.1;10.2.1 Design of Passively Targeting Theranostic Liposomes;305
5.3.2.2;10.2.2 Design of Actively Targeting Theranostic Liposomes;307
5.3.3;10.3 MRI-Guided Drug Delivery Using Thermosensitive Liposomes and HIFU;309
5.3.3.1;10.3.1 Thermosensitive Liposomes;309
5.3.3.2;10.3.2 Temperature-Triggered Local Drug Delivery Using MRI-Guided HIFU;312
5.3.4;10.4 Radiolabeled Liposomes for Combining Imaging and Therapy;314
5.3.4.1;10.4.1 Nuclear Imaging Techniques;314
5.3.4.2;10.4.2 Labeling Liposomes with Radionuclide;316
5.3.4.3;10.4.3 Quality Control of Radiolabeled Liposomes;318
5.3.4.4;10.4.4 Liposomal Radiopharmaceuticals for Cancer Imaging and Therapy;319
5.3.5;10.5 Nanohybrid Liposomal Cerasome for Theranostics;321
5.3.5.1;10.5.1 Preparation and Properties of Cerasomes;321
5.3.5.2;10.5.2 Cerasomes as Drug/Gene Carriers;323
5.3.5.3;10.5.3 Loading Functional Nanoparticles into Cerasomes for Theranostics;326
5.3.5.4;10.5.4 Cerasomal Porphyrin for Photodynamic Theranostics of Cancer;329
5.3.6;10.6 Conclusions and Perspectives;331
5.3.7;References;332